South African-based JSE Limited listed Aspen continues to increase the number of lives benefiting from its products, reaching more than 150 countries across the world. The extensive basket of Aspen products provides treatment for a broad spectrum of acute and chronic conditions experienced throughout all stages of life.
Aspen is represented in South Africa, Australia, Hong Kong, Malaysia, Philippines, Taiwan, Japan, Kenya, Nigeria, Tanzania, Uganda, Ireland, United Arab Emirates, Germany, the Netherlands, Mauritius, Brazil, Mexico, Venezuela and the United States of America. Acquisitions announced in 2013 will further extend the Group’s emerging market presence to the Commonwealth of Independent States, comprising Russia and the former Soviet Republics as well as to Central and Eastern Europe. The Group has 26 manufacturing facilities at 18 sites on 6 continents and approximately 8200 employees.
Aspen saw full year revenue surge by 53-percent to over 29-billion-Rand. Headline earnings per share were also up by 29-percent. More than three quarters of the company's business is out of South Africa. CNBC Africa's Alec Hogg spoke to Aspen CEO, Stephen Saad.